AbCellera Biologics Inc. (ABCL)

Market Cap	894.96M
Revenue (ttm)	32.96M
Net Income (ttm)	-175.80M
Shares Out	295.37M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,327,202
Open	3.230
Previous Close	3.140
Day's Range	3.030 - 3.230
52-Week Range	2.335 - 5.260
Beta	0.42
Analysts	Buy
Price Target	8.00 (+164.03%)
Earnings Date	Feb 27, 2025

About ABCL

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 586
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL
• Website: https://www.abcellera.com

Analyst Forecast

According to 3 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 164.03% from the latest price.

Price Target

$8.0

(164.03% upside)

Analyst Consensus: Buy